Merck & Co Inc

NYSE:MRK   3:59:58 PM EDT
77.71
+1.72 (+2.26%)
4:48:19 PM EDT: $77.58 -0.13 (-0.17%)
Earnings Announcements

Merck's Keytruda Reduced Risk Of Distant Metastasis Or Death By 40% Versus Placebo

Published: 09/19/2020 14:47 GMT
Merck & Co Inc (MRK) - Merck & Co -keytruda Reduced Risk of Distant Metastasis Or Death by 40% Versus Placebo As Adjuvant Treatment in Resected, High-risk Stage Iii Melanoma.
Merck is Advancing a Broad Clinical Program Evaluating Keytruda for the Early Treatment of Cancer.
Revenue is expected to be $12.63 Billion
Adjusted EPS is expected to be $1.60

Next Quarter Revenue Guidance is expected to be $13.46 Billion
Next Quarter EPS Guidance is expected to be $1.79

More details on our Analysts Page.